Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Inflammatory Bowel Diseases

Free Subscription Articles published in J Gastroenterol Retrieve available abstracts of 50 articles: HTML format

Single Articles

July 2021
1. ANDOH A, Kawahara M, Imai T, Tatsumi G, et al
   Thiopurine pharmacogenomics and pregnancy in inflammatory bowel disease.
   J Gastroenterol. 2021 Jul 21. pii: 10.1007/s00535-021-01805.
   PubMed     Abstract available
   
   
   May 2021
2. SHINZAKI S, Matsuoka K, Tanaka H, Takeshima F, et al
   Leucine-rich alpha-2 glycoprotein is a potential biomarker to monitor disease activity in inflammatory bowel disease receiving adalimumab: PLANET study.
   J Gastroenterol. 2021 May 3. pii: 10.1007/s00535-021-01793.
   PubMed     Abstract available
   
   
   April 2021
3. NAKASE H, Uchino M, Shinzaki S, Matsuura M, et al
   Evidence-based clinical practice guidelines for inflammatory bowel disease 2020.
   J Gastroenterol. 2021 Apr 22. pii: 10.1007/s00535-021-01784.
   PubMed     Abstract available
   
   
   November 2020
4. KOHYAMA A, Watanabe K, Sugita A, Futami K, et al
   Ulcerative colitis-related severe enteritis: an infrequent but serious complication after colectomy.
   J Gastroenterol. 2020 Nov 5. pii: 10.1007/s00535-020-01742.
   PubMed     Abstract available
   
   
   
5. KITA T, Ashizuka S, Ohmiya N, Yamamoto T, et al
   Adrenomedullin for steroid-resistant ulcerative colitis: a randomized, double-blind, placebo-controlled phase-2a clinical trial.
   J Gastroenterol. 2020 Nov 2. pii: 10.1007/s00535-020-01741.
   PubMed     Abstract available
   
   
   August 2020
6. NAGANUMA M
   Solving the questions regarding 5-aminosalitylate formulation in the treatment of ulcerative colitis.
   J Gastroenterol. 2020 Aug 10. pii: 10.1007/s00535-020-01713.
   PubMed     Abstract available
   
   
   January 2020
7. SUGITANI Y, Nishida A, Inatomi O, Ohno M, et al
   Sodium absorption stimulator prostasin (PRSS8) has an anti-inflammatory effect via downregulation of TLR4 signaling in inflammatory bowel disease.
   J Gastroenterol. 2020 Jan 8. pii: 10.1007/s00535-019-01660.
   PubMed     Abstract available
   
   
   December 2019
8. NAGANUMA M, Yokoyama Y, Motoya S, Watanabe K, et al
   Efficacy of apheresis as maintenance therapy for patients with ulcerative colitis in an open-label prospective multicenter randomised controlled trial.
   J Gastroenterol. 2019 Dec 6. pii: 10.1007/s00535-019-01651.
   PubMed     Abstract available
   
   
   October 2019
9. MURAKAMI Y, Nishiwaki Y, Oba MS, Asakura K, et al
   Correction to: Estimated prevalence of ulcerative colitis and Crohn's disease in Japan in 2015: an analysis of a nationwide survey.
   J Gastroenterol. 2019 Oct 23. pii: 10.1007/s00535-019-01637.
   PubMed     Abstract available
   
   
   September 2019
10. NAGANUMA M, Sugimoto S, Fukuda T, Mitsuyama K, et al
    Indigo naturalis is effective even in treatment-refractory patients with ulcerative colitis: a post hoc analysis from the INDIGO study.
    J Gastroenterol. 2019 Sep 16. pii: 10.1007/s00535-019-01625.
    PubMed     Abstract available
    
    
    August 2019
11. HIGASHIYAMA M, Sugita A, Koganei K, Wanatabe K, et al
    Correction to: Management of elderly ulcerative colitis in Japan.
    J Gastroenterol. 2019 Aug 7. pii: 10.1007/s00535-019-01606.
    PubMed     Abstract available
    
    
    July 2019
12. MURAKAMI Y, Nishiwaki Y, Oba MS, Asakura K, et al
    Estimated prevalence of ulcerative colitis and Crohn's disease in Japan in 2014: an analysis of a nationwide survey.
    J Gastroenterol. 2019 Jul 15. pii: 10.1007/s00535-019-01603.
    PubMed     Abstract available
    
    
    May 2019
13. NAGANUMA M, Sugimoto S, Suzuki H, Matsuno Y, et al
    Adverse events in patients with ulcerative colitis treated with indigo naturalis: a Japanese nationwide survey.
    J Gastroenterol. 2019 May 17. pii: 10.1007/s00535-019-01591.
    PubMed     Abstract available
    
    
    
14. PARK S, Chun J, Han KD, Soh H, et al
    Dose-response relationship between cigarette smoking and risk of ulcerative colitis: a nationwide population-based study.
    J Gastroenterol. 2019 May 15. pii: 10.1007/s00535-019-01589.
    PubMed     Abstract available
    
    
    April 2019
15. WANG T, Chen N, Ren W, Liu F, et al
    Integrated analysis of circRNAs and mRNAs expression profile revealed the involvement of hsa_circ_0007919 in the pathogenesis of ulcerative colitis.
    J Gastroenterol. 2019 Apr 29. pii: 10.1007/s00535-019-01585.
    PubMed     Abstract available
    
    
    
16. HIGASHIYAMA M, Sugita A, Koganei K, Wanatabe K, et al
    Management of elderly ulcerative colitis in Japan.
    J Gastroenterol. 2019 Apr 20. pii: 10.1007/s00535-019-01580.
    PubMed     Abstract available
    
    
    January 2019
17. NISHIMURA R, Shirasaki T, Tsuchiya K, Miyake Y, et al
    Establishment of a system to evaluate the therapeutic effect and the dynamics of an investigational drug on ulcerative colitis using human colonic organoids.
    J Gastroenterol. 2019 Jan 1. pii: 10.1007/s00535-018-01540.
    PubMed     Abstract available
    
    
    
18. YASUKAWA S, Matsui T, Yano Y, Sato Y, et al
    Crohn's disease-specific mortality: a 30-year cohort study at a tertiary referral center in Japan.
    J Gastroenterol. 2019;54:42-52.
    PubMed     Abstract available
    
    
    December 2018
19. KINOSHITA K, Katsurada T, Nishida M, Omotehara S, et al
    Usefulness of transabdominal ultrasonography for assessing ulcerative colitis: a prospective, multicenter study.
    J Gastroenterol. 2018 Dec 5. pii: 10.1007/s00535-018-01534.
    PubMed     Abstract available
    
    
    November 2018
20. IMAI T, Inoue R, Kawada Y, Morita Y, et al
    Characterization of fungal dysbiosis in Japanese patients with inflammatory bowel disease.
    J Gastroenterol. 2018 Nov 26. pii: 10.1007/s00535-018-1530.
    PubMed     Abstract available
    
    
    August 2018
21. VAN DER SLOOT KWJ, Weersma RK, Dijkstra G, Alizadeh BZ, et al
    Development and validation of a web-based questionnaire to identify environmental risk factors for inflammatory bowel disease: the Groningen IBD Environmental Questionnaire (GIEQ).
    J Gastroenterol. 2018 Aug 14. pii: 10.1007/s00535-018-1501.
    PubMed     Abstract available
    
    
    June 2018
22. KAKUTA Y, Kawai Y, Okamoto D, Takagawa T, et al
    NUDT15 codon 139 is the best pharmacogenetic marker for predicting thiopurine-induced severe adverse events in Japanese patients with inflammatory bowel disease: a multicenter study.
    J Gastroenterol. 2018 Jun 19. pii: 10.1007/s00535-018-1486.
    PubMed     Abstract available
    
    
    
23. SCHREIBER S, Dignass A, Peyrin-Biroulet L, Hather G, et al
    Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease.
    J Gastroenterol. 2018 Jun 4. pii: 10.1007/s00535-018-1480.
    PubMed     Abstract available
    
    
    
24. NAGANUMA M
    Author's reply: can budesonide form be alterative treatment for ulcerative proctosigmoiditis?
    J Gastroenterol. 2018;53:801-802.
    PubMed    
    
    
    April 2018
25. POKROTNIEKS J, Sitkin S
    A proposed treatment algorithm for mild to moderate ulcerative colitis-with an emphasis on budesonide foam and mucosal healing.
    J Gastroenterol. 2018 Apr 3. pii: 10.1007/s00535-018-1458.
    PubMed    
    
    
    February 2018
26. MATSUOKA K, Kobayashi T, Ueno F, Matsui T, et al
    Evidence-based clinical practice guidelines for inflammatory bowel disease.
    J Gastroenterol. 2018 Feb 10. pii: 10.1007/s00535-018-1439.
    PubMed     Abstract available
    
    
    November 2017
27. KAKUTA Y, Kinouchi Y, Shimosegawa T
    Pharmacogenetics of thiopurines for inflammatory bowel disease in East Asia: prospects for clinical application of NUDT15 genotyping.
    J Gastroenterol. 2017 Nov 30. pii: 10.1007/s00535-017-1416.
    PubMed     Abstract available
    
    
    October 2017
28. NAGANUMA M, Aoyama N, Tada T, Kobayashi K, et al
    Correction to: Complete mucosal healing of distal lesions induced by twice-daily budesonide 2-mg foam promoted clinical remission of mild-to-moderate ulcerative colitis with distal active inflammation: double-blind, randomized study.
    J Gastroenterol. 2017 Oct 13. doi: 10.1007/s00535-017-1399.
    PubMed     Abstract available
    
    
    September 2017
29. HANAOKA M, Ishikawa T, Ishiguro M, Tokura M, et al
    Expression of ATF6 as a marker of pre-cancerous atypical change in ulcerative colitis-associated colorectal cancer: a potential role in the management of dysplasia.
    J Gastroenterol. 2017 Sep 7. doi: 10.1007/s00535-017-1387.
    PubMed     Abstract available
    
    
    
30. UCHINO M, Ikeuchi H, Sugita A, Futami K, et al
    Pouch functional outcomes after restorative proctocolectomy with ileal-pouch reconstruction in patients with ulcerative colitis: Japanese multi-center nationwide cohort study.
    J Gastroenterol. 2017 Sep 7. doi: 10.1007/s00535-017-1389.
    PubMed     Abstract available
    
    
    August 2017
31. NISHINO K, Nishida A, Inoue R, Kawada Y, et al
    Analysis of endoscopic brush samples identified mucosa-associated dysbiosis in inflammatory bowel disease.
    J Gastroenterol. 2017 Aug 29. doi: 10.1007/s00535-017-1384.
    PubMed     Abstract available
    
    
    
32. NAGANUMA M, Aoyama N, Tada T, Kobayashi K, et al
    Complete mucosal healing of distal lesions induced by twice-daily budesonide 2-mg foam promoted clinical remission of mild-to-moderate ulcerative colitis with distal active inflammation: double-blind, randomized study.
    J Gastroenterol. 2017 Aug 4. doi: 10.1007/s00535-017-1376.
    PubMed     Abstract available
    
    
    June 2017
33. KOBAYASHI T, Matsuoka K, Yokoyama Y, Nakamura T, et al
    A multicenter, retrospective, observational study of the clinical outcomes and risk factors for relapse of ulcerative colitis at 1 year after leukocytapheresis.
    J Gastroenterol. 2017 Jun 8. doi: 10.1007/s00535-017-1356.
    PubMed     Abstract available
    
    
    May 2017
34. IHARA S, Hirata Y, Koike K
    TGF-beta in inflammatory bowel disease: a key regulator of immune cells, epithelium, and the intestinal microbiota.
    J Gastroenterol. 2017 May 22. doi: 10.1007/s00535-017-1350.
    PubMed     Abstract available
    
    
    
35. QIU Y, Chen BL, Mao R, Zhang SH, et al
    Systematic review with meta-analysis: loss of response and requirement of anti-TNFalpha dose intensification in Crohn's disease.
    J Gastroenterol. 2017;52:535-554.
    PubMed     Abstract available
    
    
    
36. RIMOLA J, Alvarez-Cofino A, Perez-Jeldres T, Ayuso C, et al
    Comparison of three magnetic resonance enterography indices for grading activity in Crohn's disease.
    J Gastroenterol. 2017;52:585-593.
    PubMed     Abstract available
    
    
    
37. BUISSON A, Hordonneau C, Goutte M, Bommelaer G, et al
    What score should be used for evaluation of Crohn's disease severity using magnetic resonance imaging?
    J Gastroenterol. 2017;52:652-653.
    PubMed    
    
    
    April 2017
38. SUZUKI Y, Motoya S, Hanai H, Hibi T, et al
    Erratum to: Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitis.
    J Gastroenterol. 2017 Apr 12. doi: 10.1007/s00535-017-1340.
    PubMed    
    
    
    March 2017
39. HIBI T, Imai Y, Senoo A, Ohta K, et al
    Efficacy and safety of golimumab 52-week maintenance therapy in Japanese patients with moderate to severely active ulcerative colitis: a phase 3, double-blind, randomized, placebo-controlled study-(PURSUIT-J study).
    J Gastroenterol. 2017 Mar 21. doi: 10.1007/s00535-017-1326.
    PubMed     Abstract available
    
    
    
40. SUZUKI Y, Motoya S, Hanai H, Hibi T, et al
    Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitis.
    J Gastroenterol. 2017 Mar 20. doi: 10.1007/s00535-017-1325.
    PubMed     Abstract available
    
    
    February 2017
41. ARAKI M, Shinzaki S, Yamada T, Arimitsu S, et al
    Age at onset is associated with the seasonal pattern of onset and exacerbation in inflammatory bowel disease.
    J Gastroenterol. 2017 Feb 6. doi: 10.1007/s00535-017-1313.
    PubMed     Abstract available
    
    
    January 2017
42. SUN M, Wu W, Liu Z, Cong Y, et al
    Microbiota metabolite short chain fatty acids, GPCR, and inflammatory bowel diseases.
    J Gastroenterol. 2017;52:1-8.
    PubMed     Abstract available
    
    
    December 2016
43. NAKAZAWA T, Notohara K, Tazuma S, Tanaka A, et al
    The 2016 diagnostic criteria for primary sclerosing cholangitis.
    J Gastroenterol. 2016.
    PubMed     Abstract available
    
    
    November 2016
44. IBORRA M, Gisbert JP, Bosca-Watts MM, Lopez-Garcia A, et al
    Erratum to: Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naive and non-naive patients.
    J Gastroenterol. 2016.
    PubMed    
    
    
    
45. CHAN HC, Ng SC
    Emerging biologics in inflammatory bowel disease.
    J Gastroenterol. 2016.
    PubMed     Abstract available
    
    
    October 2016
46. NISHIDA A, Imaeda H, Ohno M, Inatomi O, et al
    Efficacy and safety of single fecal microbiota transplantation for Japanese patients with mild to moderately active ulcerative colitis.
    J Gastroenterol. 2016.
    PubMed     Abstract available
    
    
    
47. IBORRA M, Perez-Gisbert J, Bosca-Watts MM, Lopez-Garcia A, et al
    Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naive and non-naive patients.
    J Gastroenterol. 2016.
    PubMed     Abstract available
    
    
    September 2016
48. MARTELLI L, Olivera P, Roblin X, Attar A, et al
    Cost-effectiveness of drug monitoring of anti-TNF therapy in inflammatory bowel disease and rheumatoid arthritis: a systematic review.
    J Gastroenterol. 2016.
    PubMed     Abstract available
    
    
    July 2016
49. KEDIA S, Rampal R, Paul J, Ahuja V, et al
    Gut microbiome diversity in acute infective and chronic inflammatory gastrointestinal diseases in North India.
    J Gastroenterol. 2016;51:660-71.
    PubMed     Abstract available
    
    
    June 2016
50. MUSCI JO, Cornish JS, Dabritz J
    Utility of surrogate markers for the prediction of relapses in inflammatory bowel diseases.
    J Gastroenterol. 2016;51:531-47.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Inflammatory Bowel Diseases is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: